

泌尿器科学

論文

A 欧文

A-a

- 1 . Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H: Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder. *Low Urin Tract Symptoms* 12(1): 47-53, 2020. doi: 10.1111/luts.12283. (IF: 1.592) *
- 2 . Tagami A, Tomita M, Adachi S, Tsuda K, Yamada S, Chiba K, Okazaki N, Yonekura A, Tsujimoto R, Kajiyama S, Matsubayashi S, Miyamoto T, Mochizuki Y, Ohba K, Osaki M: Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. *J Bone Miner Metab* 38(1): 78-85, 2020. doi: 10.1007/s00774-019-01028-6. (IF: 2.626) *
- 3 . Kawano H, Ando T, Shida Y, Niino D, Maemura K, Kawai K: Isolated left adrenal medullary hyperplasia. *J Cardiol Cases* 21(1): 16-19, 2020. doi: 10.1016/j.jccase.2019.08.018. (IF: 0.528)
- 4 . Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E, Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, Suzuki K : Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml. *J Urol* 203(1): 83-91, 2020. doi: 10.1097/JU.0000000000000495. (IF: 1.18) *
- 5 . Shida Y, Hakariya T, Miyata Y, Sakai H: Three cases of brain metastasis from castration-resistant prostate cancer. *Clin. Case Rep.* 8(1): 96-99, 2020. doi: 10.1002/ccr3.2587. (IF: 0.532) *
- 6 . Kitamura M, Tateishi Y, Sato S, Ota Y, Muta K, Uramatsu T, Izumo T, Mochizuki Y, Harada T, Funakoshi S, Matsuo T, Tsujino A, Sakai H, Mukae H, Nishino T: Lower serum calcium and pre-onset blood pressure elevation in cerebral hemorrhage patients undergoing hemodialysis. *Clin. Exp. Nephrol.* 24(5): 465-473, 2020. doi: 10.1007/s10157-020-01846-3. (IF: 2.801) *
- 7 . Wang M, Hiraki R, Nakamura N, Hayama T, Yasuda T, Miyata Y, Sakai H, Nakashima MN, Nakashima M, Ohyama K: Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography with Ultraviolet Detection. *J. Chromatogr. Sci.* : 2020. doi: 10.1093/chromsci/bmaa020. (IF: 1.618) *
- 8 . Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N: Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. *Cancer Sci.* 111(7): 2460-2471, 2020. doi: 10.1111/cas.14449. (IF: 6.716) *
- 9 . Mukae Y, Miyata Y, Nakamura Y, Araki K, Otsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1. *Oncol. Lett.* 20(1): 135-144, 2020. doi: 10.3892/ol.2020.11540. (IF: 2.967) ○ *
- 10 . Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Coler-Reilly A, Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, TaylorGP, Yamano Y: Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. *Orphanet J. Rare Dis.* 15(1): 175, 2020. doi: 10.1186/s13023-020-01451-3. (IF: 4.123) *
- 11 . Tsuji K, Kitamura M, Muta K, Mochizuki Y, Mori T, Sohara E, Uchida S, Sakai H, Mukae H, Nishino T: Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report. *BMC Nephrol.* 21(1): 282, 2020. doi: 10.1186/s12882-020-01940-4. (IF: 2.388) *
- 12 . Miyata Y, Araki K, Ohba K, Matsuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF- α and TGF- β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial. *Mol. Clin. Oncol.* 13(4): 29, 2020. doi: 10.3892/mco.2020.2099. (IF: 1.63) *
- 13 . Yuno Y, Miyata M, Matsuo T, Mukae Y, Otsubo A, Mitsunari K, Ohba K, Suda T, Saito S, Sakai H: Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer. *Anticancer Res.* 40(10): 5567-5575, 2020. doi: 10.21873/anticancer.14569. (IF: 2.48) ○ *

- 14 . Yuno Y, Miyata Y, Mukae Y, Otsubo A, Mitsunari K, Matsuo T, Ohba K, Sakai H: Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators. *Med Sci (Basel)* 8(4): 43, 2020. doi: 10.3390/medsci8040043. (IF: 3.738)
- 15 . Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. *Medicines*, 2019, 6, 2. *Medicines (Basel)* 7(11): 71, 2020. doi: 10.3390/medicines7110071. (IF: 1.889)
- 16 . Eguchi S, Hidaka M, Natsuda K, Hara T, Kugiyama T, Hamada T, Tanaka T, Ono S, Adachi T, Kanetaka K, Soyama A, Mochizuki Y, Sakai H: Simultaneous Deceased Donor Liver and Kidney Transplantation in a Human Immunodeficiency Virus/Hepatitis C Virus -Coinfected Patient With Hemophilia in Japan: A Case Report. *Transplant. Proc.* 52(9): 2786-2789, 2020. doi: 10.1016/j.transproceed.2020.05.005. (IF: 1.066) *
- 17 . Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. *Medicines*, 2019, 6, 2. *Medicines (Basel)* 7(11): 71, 2020. doi: 10.3390/medicines7110071. (IF: 1.889)
- 18 . Miyata Y, Araki K, Ohba K, Matsuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H: Erratum: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF- α and TGF- β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial. *Mol. Clin. Oncol.* 13(6): 78, 2020. doi: 10.3892/mco.2020.2148. (IF: 1.63) *

A-b

- 1 . Matsuo T, Miyata Y, Yuno T, Mukae Y, Otsubo A, Mitsunari K, Ohba K, Sakai H: Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer. *Molecules* 25(3): 575, 2020. doi: 10.3390/molecules25030575. (IF: 4.148) *
- 2 . Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers. *Molecules* 25(22): 5252, 2020. doi: 10.3390/molecules25225252. (IF: 4.411) *
- 3 . Miyata Y, Matsuo T, Ohba K, Mitsunari K, Mukae Y, Otsubo A, Harada J, Matsuda T, Kondo T, Sakai H: Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer. *Cancers* 12(12): 2020. doi: 10.3390/cancers12123776. (IF: 6.639) *

A-e-1

- 1 . Miyata Y, Ohba K, Matsuo T, Mitsunari K, Sakai H: A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors. *J. Clin. Oncol.* 38(6): 2020. (IF: 44.544) *
- 2 . Matsuo T, Miyata Y, Mitsunari K, Ohba K, Sakai H: Long-term outcomes of patients with locally advanced bladder cancer that underwent intra-arterial chemotherapy with/without radiotherapy for organ preservation. *J. Clin. Oncol.* 38(6): 2020. (IF: 44.544) *
- 3 . Ohtsubo A, Oshiro T, Kimura R, Miyazato M, Matsuo T, Miyata Y, Sakai H: OXIDATIVE STRESS INDUCES DETRUSOR UNDERACTIVITY AND URETHRAL DYSFUNCTION IN AGING RATS. *J. Clin. Oncol.* 203: E533-E534, 2020. (IF: 44.544) *
- 4 . Ohtsubo A, Matsuo T, Mukae Y, Mitsunari K, Ohba K, Miyata Y, Sakai H: PREOPERATIVE NUTRITIONAL STATUS OF TRANSURETHRAL LITHOTRIPSY AFFECTS DEVELOPMENT OF POSTOPERATIVE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. *J. Clin. Oncol.* 203: E275, 2020. (IF: 44.544) *
- 5 . Mukae Y, Miyata Y, Ohtsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: KIBRA AND PHOSPHORYLATED LATS-2 ARE NEGATIVELY ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND ARE PROGNOSTIC INDICATORS IN PATIENTS WITH RENAL CELL CARCINOMA. *J. Clin. Oncol.* 203: E113-E114, 2020. (IF: 44.544) *
- 6 . Miyata Y, Yuno T, Mukae Y, Mitsunari K, Matsuo T, Ohba K, Sakai H, Otsubo A: INHIBITION OF E-TYPE PROSTANOID RECEPTOR 1 INHIBITS THE MALIGNANT POTENTIAL OF PROSTATE CANCER CELLS IN AN ANIMAL MODEL. *J. Clin. Oncol.* 203: E560, 2020. (IF: 44.544) *

B 邦文

B-a

- 1 . 宮田康好, 松尾朋博, 光成健輔, 大庭康司郎, 酒井英樹: 進行性尿路がんの2次治療における地域の医療・福祉サービスとの診療連携の有用性: 生命予後やQoLへの影響. *泌尿器科紀要* 66(4): 107-113, 2020.

2. 望月 保志,大庭 康司郎,宮田 康好,酒井 英樹,大野 慎一郎,日高 匡章,江口 晋8: 複合臓器移植の経験と泌尿器科医の役割. 西日本泌尿器科 82(3): 350-356, 2020.
3. 望月 保志,計屋 知彰,大庭 康司郎,宮田 康好,酒井 英樹: 【副甲状腺外科治療を極める】 二次性副甲状腺機能亢進症の治療変遷と外科治療. 日本内分泌外科学会雑誌 37(4): 237-241, 2020.
4. 計屋 知彰,酒井 英樹: 【副腎皮質疾患】 長崎大学における副腎皮質癌の診療の実際 泌尿器科の立場から. 日本内分泌外科学会雑誌 37(4): 276-281, 2020.

B-b

1. 酒井英樹1: 【前立腺がんの過剰診断・過剰治療の解決策】 日本人の前立腺がん 罹患率と死亡率の動向. 泌尿器科 11(1): 1-6, 2020.
2. 計屋 知彰: 【前立腺癌治療の合併症・副作用マネージメント】 骨修飾薬 投与前の注意と投与中の副作用対策. Prostate Journal 7(1): 76-79, 2020.
3. 酒井英樹4: 【泌尿器科診療の最新スタンダード-平成の常識は令和の非常識】 内分泌疾患 原発性アルドステロン症. 臨床泌尿器科 74(4): 190-193, 2020.
4. 松尾 朋博,大坪 亜紗斗,迎 祐太,湯野 努,光成 健輔,大庭 康司郎,宮田 康好,酒井 英樹: 【夜間頻尿治療の最先端】 夜間頻尿の治療 行動療法に関する最前線. 日本排尿機能学会誌 30(2): 107-113, 2020.
5. 松尾朋博,宮田康好,酒井英樹: これが最新版!過活動膀胱のトリセツ (過活動膀胱の治療と問題点) 行動療法. 臨床泌尿器科 74(8): 570-574, 2020.
6. 計屋 知彰,酒井 英樹: 【前立腺癌の薬物療法:ホルモン感受性癌から去勢抵抗性癌まで】 新規ホルモン治療薬. Prostate Journal 7(2): 171-175, 2020.
7. 志田洋平, 酒井英樹: 【前立腺肥大症の新しい外科的治療の選択肢】 前立腺肥大症の下部尿路症状に対する経尿道的水蒸気治療. 泌尿器科 12(4): 396-400, 2020.
8. 計屋 知彰: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器科専門領域の最新情報(vol.5) 副腎腫瘍 褐色細胞腫の診断と治療. Uro-Lo: 泌尿器Care & Cure 25(6): 864-867, 2020.
9. 中村裕子,岡田みずほ,小渕美樹子,志田洋平,酒井英樹: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器科専門領域の最新情報(vol.5) 副腎腫瘍 副腎腫瘍手術患者の看護 病棟看護師の役割. Uro-Lo: 泌尿器Care & Cure 25(6): 868-873, 2020.

B-e-1

1. 大庭 康司郎,酒井 英樹: 各科(外科、婦人科、泌尿器科)における側方リンパ節(骨盤リンパ節)郭清意義と実際 泌尿器癌に対する骨盤内リンパ節郭清の意義と実際. 日本外科系連合学会誌 45(5): 569, 2020.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	SCI	合計	B-a	B-b	B-c	B-d	B-e	合計	総計
2020	18	3	0	0	6	23	27	4	9	0	0	1	14	41

学会発表数一覧

	A-a	A-b シンポジウム	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2020	0	0	3	3	0	2	34	36	39

論文総数に係る教員生産係数

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2020	0.659	3.000	0.852	2.556

Impact Factor 値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2020	323.855	35.984	14.081